What is she best known for?
The fields of study she is best known for:
The scientist’s investigation covers issues in Genetics, Cell biology, Cilium, Ciliopathies and Renal cell carcinoma.
With her scientific publications, her incorporates both Genetics and CREB-binding protein.
Her studies deal with areas such as Tumor suppressor gene and Zebrafish as well as Cell biology.
The concepts of her Cilium study are interwoven with issues in Cystic kidney and Organelle.
Her Ciliopathies research is multidisciplinary, incorporating perspectives in Human genetics, Ciliopathy and Polycystic kidney disease.
In her study, Sunitinib is strongly linked to Urology, which falls under the umbrella field of Renal cell carcinoma.
Her most cited work include:
- Caught up in a Wnt storm: Wnt signaling in cancer. (1295 citations)
- Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP (1025 citations)
- Mutations in the APC tumour suppressor gene cause chromosomal instability (611 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Genetics, Cilium, Cell biology, Cancer research and Internal medicine.
Her Genetics research integrates issues from Molecular biology and Disease.
Her Cilium research also works with subjects such as
- Ciliopathy which intersects with area such as Ciliopathies, Nephronophthisis and Joubert syndrome,
- DNA damage and related Cell cycle.
Rachel H. Giles interconnects Suppressor and Zebrafish in the investigation of issues within Cell biology.
The study incorporates disciplines such as Tumor suppressor gene, Cancer, Wnt signaling pathway and Von Hippel–Lindau disease in addition to Cancer research.
Her Internal medicine research is multidisciplinary, incorporating elements of Endocrinology and Oncology.
She most often published in these fields:
- Genetics (24.39%)
- Cilium (23.17%)
- Cell biology (21.95%)
What were the highlights of her more recent work (between 2015-2021)?
- Renal cell carcinoma (10.98%)
- Kidney cancer (9.15%)
- Internal medicine (18.29%)
In recent papers she was focusing on the following fields of study:
Rachel H. Giles mainly focuses on Renal cell carcinoma, Kidney cancer, Internal medicine, Cell biology and Cilium.
Her study looks at the intersection of Internal medicine and topics like Oncology with Frameshift mutation.
Her work carried out in the field of Cell biology brings together such families of science as Transgene and Zebrafish.
Her studies in Cilium integrate themes in fields like Phenotype, Ciliopathies, Ciliopathy and Ciliary tip.
The subject of her Phenotype research is within the realm of Genetics.
Her study on Genetics is mostly dedicated to connecting different topics, such as Disease.
Between 2015 and 2021, her most popular works were:
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. (329 citations)
- An organelle-specific protein landscape identifies novel diseases and molecular mechanisms (126 citations)
- Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer (105 citations)
In her most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Renal cell carcinoma, Genetics, Urology, Kidney cancer and Sunitinib.
Genetics and Disease are frequently intertwined in her study.
Rachel H. Giles combines subjects such as Cancer, Systematic review, Clear cell renal cell carcinoma and Guideline with her study of Urology.
Her work deals with themes such as Randomized controlled trial and Adjuvant therapy, which intersect with Kidney cancer.
Her work investigates the relationship between Molecular genetics and topics such as Phenotype that intersect with problems in Cilium.
Her research investigates the connection between Ciliary transition zone and topics such as Cell biology that intersect with problems in Intraflagellar transport.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
